Clinical Trial

Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL

Study acronym: MTR²
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in patients ineligible for HCT-ASCT with Primary Central Nervous System Lymphoma (PCNSL)
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-10-14; most recent amendment 2025-08-07.
Status change: Not Yet Recruiting → Recruiting 2025-01-27
Trial Details
NCT Number NCT05583071
Lead Sponsor University of Cologne
Collaborators: Incyte Corporation
Conditions Non-Hodgkin Lymphoma
Enrollment 20 participants
Start Date 2024-08-23
Primary Completion 2027-02 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-08-13